
==== Front
J Int Med Res
J Int Med Res
IMR
spimr
The Journal of International Medical Research
0300-0605
1473-2300
SAGE Publications Sage UK: London, England

39246070
10.1177/03000605241274581
10.1177_03000605241274581
Case Report and Case Series
Acute lymphoblastic leukemia with pneumatosis cystoides intestinalis after hematopoietic stem cell transplantation: a case report
https://orcid.org/0009-0006-0837-5175
You Sha-Sha
Lin Zhou-Ning
Sheng Li-Xia
Lai Yan-Li
Department of Hematology, 117881 The First Affiliated Hospital of Ningbo University , Ningbo, China
Li-Xia Sheng, Department of Hematology, The First Affiliated Hospital of Ningbo University, 1601 Airport South Road, Ningbo, Zhejiang 315502, China. Email: slx800408@163.com
9 2024
9 9 2024
52 9 0300060524127458114 3 2024
24 7 2024
© The Author(s) 2024
2024
SAGE Publications
https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Pneumatosis cystoides intestinalis (PCI) is a rare condition characterized by air accumulation within the subserosa or submucosa of the gastrointestinal wall. We herein report a case involving a woman in her early 30s who developed PCI after undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic leukemia. The patient had a history of multiple COVID-19 infections. Imaging revealed extensive pneumoperitoneum and mesenteric emphysema; nevertheless, the patient remained clinically stable with a benign abdominal examination. She eventually recovered after 1 month of conservative treatment. We believe the PCI in this case had a multifactorial etiology, potentially involving both HSCT and COVID-19. Raising awareness of PCI may help avoid unnecessary surgical interventions and associated morbidity.

Pneumatosis cystoides intestinalis
acute lymphoblastic leukemia
COVID-19
treatment
graft-versus-host disease
immunosuppression
typesetterts2
==== Body
pmcIntroduction

Pneumatosis cystoides intestinalis (PCI) is a relatively rare condition characterized by multiple gas-filled cysts in the subserosa or submucosa of the intestinal wall, typically involving the colon and small intestine. 1 PCI often lacks specific clinical manifestations and is usually asymptomatic, making it prone to misdiagnosis or underdiagnosis, particularly when detected incidentally during imaging examinations. Although PCI is generally benign with a favorable prognosis, severe cases can lead to complications such as intestinal obstruction, bleeding, perforation, and septic shock. 2 These complications may be fatal if not treated aggressively.

We recently treated a patient who had undergone allogeneic hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic leukemia and had repeatedly tested positive for COVID-19. PCI was diagnosed based on computed tomography (CT) findings and confirmed through multidisciplinary discussions. Following conservative treatment, the patient’s intestinal gas resolved, and she was discharged in an improved condition.

Case presentation

A woman in her early 30s presented with a 3-day history of fever. She had been diagnosed with acute lymphoblastic leukemia more than 1 year previously and had received various chemotherapy regimens combined with immunotherapy agents. She subsequently underwent allogeneic HSCT followed by the administration of immunosuppressive drugs to prevent graft-versus-host disease (GVHD). After discharge, the patient repeatedly tested positive for COVID-19 and underwent several courses of antiviral medications.

On this occasion, the patient had developed a fever and sought treatment at another hospital, where she again tested positive for COVID-19. A chest CT scan revealed new nodules with cavity formation in the upper lobes of both lungs, indicating potential infectious lesions. Additionally, a CT scan revealed multiple gas shadows in the mesentery and retroperitoneum, as well as gas accumulations in the colon wall, possibly due to ischemic infection. She was then referred to our hospital for further management.

Upon admission, enhanced CT angiography of the small intestinal arteries showed multiple gas accumulations around the colorectal wall and retroperitoneum (Figure 1), along with thickening and strengthening of the distal ileum wall and dilation of the intestinal cavity. Physical examination revealed a soft abdomen with mild tenderness but no rebound pain or muscle tension. Given the possibility of intestinal perforation, an urgent multidisciplinary consultation was held to discuss a potential diagnosis of PCI. With the patient’s consent, we implemented various conservative measures, including fasting, gastrointestinal decompression, antibiotics, and component blood transfusion.

Figure 1. Computed tomography angiography scan at admission. The red arrows show scattered gas accumulation around the colorectal wall and retroperitoneum.

A follow-up CT scan 1 week later showed a significant reduction in abdominal gas absorption compared with the previous imaging findings (Figure 2). A further total abdominal CT scan 2 weeks later revealed no free gas in the abdominal cavity. The patient’s condition continued to steadily improve, and she was discharged from the hospital 1 month later.

Figure 2. Computed tomography scan showing less scattered gas compared with the previous results.

Discussion

PCI is a rare disease with an incidence of approximately 0.03%. 3 It is highly suspected in patients with intestinal pneumoperitoneum but without acute abdominal manifestations. PCI can be classified as primary or secondary, accounting for approximately 15% and 85% of cases, respectively. 4

The exact etiology and pathogenesis of PCI are unknown. Various clinical factors have been implicated, 5 including gastrointestinal disorders, chronic obstructive pulmonary disease, infection by gas-producing bacteria, and the use of α-glucosidase inhibitors. However, no single explanation can account for all cases of PCI.

PCI can occur in patients with hematological diseases after HSCT, especially in patients with cutaneous or gastrointestinal GVHD.6,7 Previous studies8,9 have demonstrated a significantly higher incidence of PCI in children treated with allogeneic HSCT and in children with GVHD. A study by Wallace et al. 10 involving 990 children with HSCT showed that the systemic use of steroid hormones was associated with an elevated incidence of PCI. The most likely reason for this is the development of neutropenia following cytotoxic chemotherapy. The gas released by the proliferation of intestinal bacteria increases the intestinal pressure and breaks down the intestinal mucosal barrier, allowing the gases to gradually accumulate in the submucosal area. Myeloablative chemotherapy regimens for HSCT and immunosuppressive prophylaxis for GVHD result in prolonged neutropenia, which is considered a risk factor for the development of PCI.

A few patients have developed PCI after receiving molecularly targeted therapies, including adult patients treated with bevacizumab, sunitinib, and gefitinib. 11 Kim et al. 12 reported a case of an 11-year-old patient with relapsed precursor B-cell acute lymphoblastic leukemia who developed PCI after treatment with blinatumomab.

In the current case, the patient had undergone chemotherapy and immunotherapy within the past 6 months and had received immunosuppressive agents for GVHD prophylaxis following allogeneic HSCT. These factors are important contributors to the development of PCI. Furthermore, the patient had repeatedly tested positive for COVID-19 after transplantation. However, reports of PCI occurring in combination with HSCT or COVID-19 are limited.

Wong et al. 13 revealed a mortality rate of up to 77.8% among nine patients with COVID-19 infection combined with PCI. Following a diagnosis of PCI, most patients experienced worsening of their condition, such as increased vasopressin requirements and acute kidney injury. The mean time to death after PCI diagnosis was only 6.4 days, suggesting that PCI may be an unfavorable prognostic indicator in patients with COVID-19. Previous studies have indicated that COVID-19 may invade gastrointestinal cells, disrupt the integrity of the intestinal wall, and disturb normal gut flora, resulting in increased mucosal permeability and gas dissection into the bowel wall. 14

The clinical manifestations and laboratory tests associated with PCI are nonspecific. 15 CT scans are considered particularly valuable for diagnosing PCI, 16 but laparoscopy or surgical exploration may be necessary when noninvasive tests fail to confirm the diagnosis.

To date, there are no clear guidelines or expert consensus on the management of PCI, and its prognosis depends on the severity of the condition and associated comorbidities. Asymptomatic or mildly symptomatic patients generally do not require specific treatment, with 50% improving spontaneously and up to 70% experiencing symptom relief with nonsurgical interventions. 4 Conservative treatment options include hyperbaric oxygen therapy to increase oxygen partial pressure and facilitate gas diffusion from cysts into the bloodstream as well as gastrointestinal decompression to relieve symptoms. Antibiotics may also be used to inhibit the growth of gas-producing bacteria in the intestines. However, surgical resection of the affected bowel segments is necessary in patients with significant abdominal symptoms or acute complications such as severe recurrent bloody stools, intestinal obstruction, torsion, or necrosis. 4 Previous research has shown that low pH levels (<7.3), reduced bicarbonate levels (<20 mEq/L), elevated lactate levels (>2 mmol/L), increased amylase levels (>200 U/L), and the presence of portal gas are insufficient predictors of intestinal necrosis or mortality in patients with PCI. 17

Conclusion

PCI is a rare disease with an unknown etiology and pathogenesis. Treatment should be tailored to the patient’s clinical symptoms and diagnostic test results. This case highlights the importance of raising awareness about PCI and provides valuable information regarding its potential etiology and more rational therapeutic approaches. In patients with hematologic diseases, PCI may be associated with prolonged immunodeficiency due to chemotherapy and other treatments, possibly in combination with various pathogenic microbial infections. Clinical awareness of PCI is crucial to avoid unnecessary surgical interventions. Case reports play an essential role in sharing unique clinical experiences, and further research is needed to develop better diagnostic techniques and treatment regimens.

The reporting of this study conforms to CARE guidelines. 18

Acknowledgements

The authors are grateful to the staff in the medical records section of the hospital for providing the patient’s medical records.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics and informed consent statements

This study did not require ethics committee approval as it did not involve animal or human clinical trials. In accordance with the ethical principles outlined in the Declaration of Helsinki, all participants provided informed consent before participating in the study. The anonymity and confidentiality of the participants were guaranteed, and participation was completely voluntary. Informed consent for publication was not applicable because all the patient’s details were de-identified.

Author contributions: Sha-Sha You: writing, conceptualization, methodology, data curation; Zhou-Ning Lin and Yan-Li Lai: conceptualization, methodology, investigation; Li-Xia Sheng: supervision, editing. All authors have read and approved the final manuscript.

The authors declare that there is no conflict of interest.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD: Sha-Sha You https://orcid.org/0009-0006-0837-5175
==== Refs
References

1 Yang L Zhong X Yang H , et al . Pneumatosis cystoides intestinalis associated with etoposide in hematological malignancies: a case report and a literature review. BMC Gastroenterol 2022; 22 : 150.35346061
2 Lee KS Hwang S Hurtado RS , et al . Distinguishing benign and life-threatening pneumatosis intestinalis in patients with cancer by CT imaging features. AJR Am J Roentgenol 2013; 200 : 1042–1047.23617487
3 Ma W Zhang C Sun MW , et al . Pneumatosis cystoides intestinalis: a case report and literature review. Asian J Surg 2023; 46 : 2581–2582.36642552
4 Ling F Guo D Zhu L. Pneumatosis cystoides intestinalis: a case report and literature review. BMC Gastroenterol 2019; 19 : 176.31694581
5 Widana PP Fernandez A. Pneumatosis cystoides intestinalis: a benign cause of pneumoperitoneum. J Med Cases 2022; 13 : 188–191.35464335
6 Venkataramani V Seif AHA Schulze MH , et al . Intestinal pneumatosis associated with tuberculosis after allogeneic hematopoietic stem cell transplantation. Acta Haematol 2017; 137 : 51–54.27923223
7 Keklik F Cayci Z Arndt P , et al . Spontaneous complete resolution of pneumomediastinum and pneumatosis intestinalis caused by acute GVHD. Am J Hematol 2016; 91 : 749–750.26890819
8 Baldari D Pizzicato P Tambaro FP , et al . Pneumatosis cystoides intestinalis, a rare case in a pediatric patient following allogeneic hematopoietic stem cell transplantation: CT findings and literature review. Radiol Case Rep 2021; 16 : 3120–3124.34457100
9 Arman BO Demir AM Akcabelen YM , et al . Pneumatosis cystoides intestinalis: a rare complication after hematopoietic stem cell transplantation. Pediatr Transplant 2021; 25 : e14136.34505744
10 Wallace G Rosen N Towbin AJ , et al . Pneumatosis intestinalis after hematopoietic stem cell transplantation: when not doing anything is good enough. J Pediatr Surg 2021; 56 : 2073–2077.33455803
11 Shinagare AB Howard SA Krajewski KM , et al . Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management. AJR Am J Roentgenol 2012; 199 : 1259–1265.23169717
12 Kim SE Lee SM Kim JY. Blinatumomab-related pneumatosis intestinalis in a pediatric patient with relapsed acute lymphoblastic leukemia: a case report. J Oncol Pharm Pract 2021; 27 : 2045–2048.34053359
13 Wong K Kim DH Khanijo S , et al . Pneumatosis intestinalis in COVID-19: case series. Cureus 2020; 12 : e10991.33209547
14 Meini S Zini C Passaleva MT , et al . Pneumatosis intestinalis in COVID-19. BMJ Open Gastroenterol 2020; 7 : e000434.
15 Aygüneş U Karagün BŞ Şaşmaz İ , et al . Pneumatosis cystoides intestinalis mimicking free intraabdominal air following chemotherapy for relapsed acute myeloblastic leukemia in a transplanted neutropenic child: a case report. Turk J Pediatr 2023; 65 : 693–697.37661686
16 Azzaroli F Turco L Ceroni L , et al . Pneumatosis cystoides intestinalis. World J Gastroenterol 2011; 17 : 4932–4936.22171137
17 Takase A Akuzawa N Naitoh H , et al . Pneumatosis intestinalis with a benign clinical course: a report of two cases. BMC Res Notes 2017; 10 : 319.28743290
18 Gagnier JJ Kienle G Altman DG , et al . CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. Headache 2013; 53 : 1541–1547.24266334
